The First End-to-End AI-Designed Drug Has Phase 2 Data. What Rentosertib’s Results Mean for the Pipeline.
7 min read7 min read 7 min read 7 min read 6 min read A 118.7 mL separation in forced vital capacity between treatment and placebo. Twelve weeks. Seventy-one patients. That is the data point the AI drug discovery field has been waiting for, and it arrived in June 2025 when Insilico Medicine published Phase IIa results …